Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04389437
Recruiting Not applicable

OCT-Angiography and Adaptive Optics in Patients With Memory Impairment

NCT04389437 · tracked via the Priya Life Science France tracker
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Not applicable
Started
2020-06-26
Last updated
2025-09-29

Condition(s) studied

AmnesiaAlzheimer DiseaseLewy Body DiseaseParkinsons Disease With Dementia

Investigational drug(s) / intervention(s)

Ophthalmological examBlood pressure measurement

Ophthalmological exam: OCT-A and AO

Blood pressure measurement: Blood pressure measurement before the ophthalmological exam

Study summary

Studies suggest an association between retinal abnormalities and NCD (Neuro Cognitive Disorders) whether they are linked to proven or prodromal Alzheimer's disease (aMCI : amnestic mild cognitive impairment), or to other neurodegenerative diseases such as frontotemporal dementia or Lewy body diseases.

These retinal anomalies objectified by OCT-A (Optical coherence tomography angiography) and adaptive optics (AO) appear different depending on the pathologies and could therefore serve as markers in vivo of the pathophysiological processes underlying NCD.

No study to date has studied the retina and its vessels in NCD using adaptive optics. In this pilot study, we are proposing a combination of two new ophthalmological imaging techniques (OCT-A and AO), which allow rapid in vivo analysis in a completely non-invasive way of the morphology of small vessels as well as architecture of the retina to better specify the retinal anomalies associated with NCD. We will compare the parameters in OCT-A and AO between patients with NCD and controls without NCD (with memory complaint or without) and will seek to determine if there are different profiles according to the causes of NCD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patient presenting in memory consultation for memory complaint or person accompanying a patient in memory consultation for memory complaint Exclusion Criteria: * pregnant or lactating women * history of known non-degenerative neurological pathology (tumor, stroke territorial, in particular multiple sclerosis) * history of retinal pathology * ametropia greater in absolute value than 3 diopters on the sphere, or/and 1.5 diopters on the cylinder. * history of taking ethambutol for more than 2 months * history of takingsynthetic antimalarial for more than 2 years * Mini Mental State Score (MMS) and / or Montreal Cognitive Assessment (MoCA) \<10 for patients and 26 for accompanying persons * MRI contraindication (for patients only)

Primary outcome measure(s)

  • Wall to lumen ratio (WLR) — Baseline (Inclusion)
    Measured in adaptive optics, compared between patients case with NCD and patient controls without NDC found

Trial sites (1)

FacilityCityRegionStatus
Hôpital Fondation A. de Rothschild Paris France Recruiting

More Fondation Ophtalmologique Adolphe de Rothschild trials in France

Efficacy of Daily IV Administration of Dornase Alfa up to 14 Days Post Subarachnoid Hemorrhage on Functional Independence at 6 Months Recruiting
Anatomical and Functional Predictions of Blindsight Capabilities in Patients With Lateral Hemianopsia Starting soon
Long Term Follow-up After Embolization of Brain Arteriovenous Malformations Recruiting
Validation of a Virtual Reality Test for the Assessment of Visually Impaired Patients Undergoing Low Vision Rehabilitation Recruiting
Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations Recruiting

Other trials for the same condition

Mitochondrial Function and Metabolomic Profile in Alzheimer's Disease and Related Dementias Recruiting
Deep Learning on Amyloid Positons Emission Tomography Recruiting
Identification of Diagnosis Biomarkers in the Tears of Alzheimer's Disease Patients: The COG-EYE Pilot Study Recruiting
Nalysis of the Periodontal Microbiota in Elderly Subjects With and Without Alzheimer's Disease: a Case Control Study Recruiting
Cohort of Patients with Alzheimer's Disease and Their Families. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04389437 on ClinicalTrials.gov ↗ ← All trials in France